Drug Trial Radar · NCT06989671
SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC
Last checked: Nov 19, 2026Latest source record: Aug 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
430
Planned (sponsor's estimate)
Start
Aug 30, 2025
Primary completion
Dec 30, 2027
Study completion Jul 30, 2028
Sponsor
- Lead sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II study of anti-nectin-4 ADC combined with the EGFR monoclonal antibody and the PD-1 monoclonal antibody in participants with advanced head and neck squamous cell carcinoma.
Conditions
- Head and Neck Squamous Cell Carcinoma
Interventions
JMT101Drug
JMT101 Q2W or Q3W, intravenous injection
SYS6002Drug
SYS6002 Q2W or Q3W, intravenous injection
SG001Drug
SG001 Q2W or Q3W, intravenous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting Toxicities (DLTs)Time frame: Up to 28 days
- Incidence of Adverse Events (AEs)Time frame: Up to approximately 2 years
- Maximum Tolerated Dose (MTD)Time frame: Up to approximately 2 years
- Objective Response Rate (ORR)Time frame: Up to approximately 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.